Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI-Reference-Cited by-同舟云学术

Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HI

Published:2020-03-11 Issue:6 Volume:55 Page:e4506
ISSN:1076-5174
Container-title:Journal of Mass Spectrometry
language:en
Short-container-title:J Mass Spectrom

Author:

Courlet Perrine¹^ORCID,Alves Saldanha Susana¹,Cavassini Matthias²,Marzolini Catia³⁴,Choong Eva¹,Csajka Chantal⁵⁶⁷,Günthard Huldrych F.⁸⁹,André Pascal¹,Buclin Thierry¹,Desfontaine Vincent¹,Decosterd Laurent Arthur¹^ORCID

Affiliation:

1. Service of Clinical Pharmacology; Lausanne University Hospital and University of Lausanne; Lausanne Switzerland

2. Service of Infectious Diseases; Lausanne University Hospital and University of Lausanne; Lausanne Switzerland

3. Division of Infectious Diseases and Hospital Epidemiology; University Hospital of Basel; Basel Switzerland

4. University of Basel; Basel Switzerland

5. Centre for Research and Innovation in Clinical Pharmaceutical Sciences; University Hospital and University of Lausanne; Lausanne Switzerland

6. Institute of Pharmaceutical Sciences of Western Switzerland; University of Geneva, University of Lausanne; Geneva Switzerland

7. School of Pharmaceutical Sciences; University of Geneva; Geneva Switzerland

8. Division of Infectious Diseases and Hospital Epidemiology; University Hospital Zurich; Switzerland

9. Institute of Medical Virology, Swiss National Reference Centre for Retroviruses; University of Zurich; Zurich Switzerland

Funder

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Spectroscopy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jms.4506/fullpdf

Reference52 articles.

1. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel;Saag;JAMA,2018

2. Adherence and Viral Suppression Among Participants of the Patient-centered Human Immunodeficiency Virus (HIV) Care Model Project: A Collaboration Between Community-based Pharmacists and HIV Clinical Providers;Byrd;Infect Dis Soc Am,2020

3. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality;Glass;AIDS,2015

4. Long-acting HIV drugs advanced to overcome adherence challenge;Dolgin;Nat Med,2014

5. Mills A. The future of long-acting injectable ART: how will patients respond? 2020 https://www.clinicaloptions.com/hiv/clinicalthought?q&sortBy&sortOrder=asc&page=1

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update;Journal of Chromatography B;2024-02

2. Population pharmacokinetic analysis of doravirine in real‐world people with HIV;British Journal of Clinical Pharmacology;2024-01-16

3. Development, validation and clinical implementation of a UPLC-MS/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2024-01

4. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland;The Lancet Regional Health - Europe;2024-01

5. Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIV;Clinica Chimica Acta;2024-01